|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we studied the effect of the novel selective ATR kinase inhibitor BAY 1895344 on tumor cell growth and viability.
|
31582533 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of ATR with AZD6738 enhanced cisplatin-induced growth inhibition of HNSCC cell lines and tumors, in association with increased apoptosis signaling and DNA damage.
|
31345392 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Oncogene-induced replication stress serves as a tumour specific vulnerability and rationale for the clinical development of inhibitors targeting the DNA damage response (DDR) kinases (CHK1, ATR, ATM and WEE1).
|
31500184 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In an orthotopic breast cancer model, tumor-selective synthetic lethality of the combination of bioavailable ATR and Wee1 inhibitors led to tumor remission and inhibited metastasis with minimal side effects.
|
30645202 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Limited data have been published about the effect of these drugs on the tumor microenvironment.<b>Experimental Design:</b> We used an immunocompetent mouse model of HPV-driven malignancies to investigate the ATR inhibitor AZD6738 in combination with fractionated radiation (RT).
|
30770349 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ATR inhibitor VE822 combined with PARPi extended survival of mice bearing GSC-derived orthotopic tumors, irrespective of PARPi-sensitivity.
|
31266951 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i>, simultaneous inhibition of ATR and GLUT1 significantly reduced tumor volume gain in an autochthonous mouse model of <i>Kras<sup>G12D</sup></i> -driven soft tissue sarcoma.
|
31405847 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ATR inhibition increased the sensitivity of all peritoneal metastasis-derived organoids to MMC, as the IC50 decreased 2·6-12·4-fold to well below concentrations commonly attained in clinical practice.
|
31197820 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
|
31273061 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, ATR-deficient fibroblasts enhanced tumor growth and aggressiveness in orthotopic breast tumor xenografts.
|
30410668 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Accordingly, decreased p38α signaling results in impaired ATR activation and homologous recombination repair, with concomitant increases in replication stress, DNA damage, and chromosome instability, leading to cancer cell death and tumor regression.
|
29805078 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because Pol η is aberrantly expressed in several tumor types, our results are critical for developing more effective chemotherapy approaches and identify coinhibition of Pol η and ATR as a potential therapeutic strategy.
|
30297532 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status.
|
30057890 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the potential effects of ATR inhibitors on immune response in the tumor microenvironment, especially on the expression of immune checkpoint-related proteins, remain elusive.
|
30094103 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Purpose Our preclinical work identified depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and showed that ATR inhibition sensitizes tumors to TOP1 inhibitors.
|
29252124 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An association with BC survival and aggressive tumour characteristics was detected for the genes ATR (rs2227928: HR = 1.63; 95% CI 1.00-2.64, dominant model), RUNX1 (rs17227210: HR = 3.50, 95% CI 1.42-8.61, recessive model) and TTN (rs2303838: HR = 2.36; 95% CI 1.04-5.39; rs2042996: HR = 2.28; 95% CI 1.19-4.37, recessive model).
|
28238063 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A <i>BRCA2</i><sup>MUT</sup> PDX with high p-CHK1 demonstrated a similar delay of tumor growth in response to PARP, CHK1, and ATR inhibitors.
|
28097235 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
|
28273450 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the combinations of PARPi with ATRi or CHK1i were synergistic in causing tumor suppression in a <i>BRCA2</i><sup>MUT</sup> PDX with the PARPi-ATRi combination inducing tumor regression and in most cases, complete remission.<b>Conclusions:</b> PARPi causes increased reliance on ATR/CHK1 for genome stability, and combination PARPi with ATR/CHK1i is more effective than PARPi alone in reducing tumor burden in <i>BRCA</i><sup>MUT</sup> models.<i></i>.
|
27993965 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We review how signalling through the ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR), and DNA-dependent protein kinases (DNA-PK) influences viral life cycles, and how their manipulation by viral proteins may contribute to tumour formation.This article is part of the themed issue 'Human oncogenic viruses'.
|
28893936 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On the one hand, telomere shortening can exert a tumour-suppressive effect through the proliferation arrest induced by activating the kinases ATM and ATR at unprotected chromosome ends.
|
28096526 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ALT phenotype was commonly seen in tumors, indicating that ATR inhibitors, which were recently suggested as possible new drugs for ATRX-deficient tumors, could provide a potential novel therapeutic option for ULMS.
|
26891131 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The heterogenous ribonucleoprotein A18 (hnRNP A18) promotes tumor growth by coordinating the translation of selected transcripts associated with proliferation and survival. hnRNP A18 binds to and stabilizes the transcripts of pro-survival genes harboring its RNA signature motif in their 3'UTRs. hnRNP A18 binds to ATR, RPA, TRX, HIF-1α and several protein translation factor mRNAs on polysomes and increases de novo protein translation under cellular stress.
|
26824423 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study suggests that combining an ATR inhibitor to lower the threshold by which a Chk1 inhibitor induces replication stress, DNA damage and tumour cell death in a wide range of cancer types may be a useful clinical approach.
|
27693461 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, ATR inhibition as a single agent exhibited antitumoral activity, both reducing tumor burden after establishment and preventing tumors from growing, in an immunocompetent allograft mouse model of AML(MLL) and in xenografts of a human AML-MLL cell line.
|
27625305 |
2016 |